56865-08-8

Basic information

• Product Name: 1-(2-chloroethyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione
• Synonyms: 1-(2-Chloroethyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 1-(2-Chloroethyl)-3,7-dimethylxanthine
• CAS NO: 56865-08-8
• Molecular Formula: C₉H₁₁ClN₄O₂
• Molecular Weight: 242.6622
• Mol File: 56865-08-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 465.7°C at 760 mmHg
• Flash Point: 235.5°C
• Density: 1.51g/cm³
• Vapor Pressure: 7.51E-09mmHg at 25°C
• Refractive Index: 1.671
• CAS DataBase Reference: 1-(2-chloroethyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroethyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione(56865-08-8)
• EPA Substance Registry System: 1-(2-chloroethyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione(56865-08-8)

Safety Data

• Hazardous Substances Data: 56865-08-8(Hazardous Substances Data)

Usage

Description

1-(2-chloroethyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione, also known as Temozolomide, is a chemotherapy drug that is primarily used to treat certain types of brain tumors. It is a prodrug, which means it is metabolized in the body to its active form, and it works by disrupting the growth and spread of cancer cells. Temozolomide is known for its effectiveness against glioblastoma, an aggressive brain tumor, and is also used for other brain tumors and certain types of melanoma.

Uses

Used in Oncology:
Temozolomide is used as an anticancer agent for the treatment of glioblastoma, an aggressive brain tumor. It is effective in inhibiting the growth and spread of cancer cells by interfering with their DNA repair mechanisms, leading to cell death. The drug is also used for other types of brain tumors and certain melanomas, showcasing its versatility in oncological applications.
Used in Combination Therapy:
In addition to its standalone use, Temozolomide is often used in combination with other cancer treatments to enhance the overall therapeutic effect. This combination approach can improve patient outcomes by increasing the efficacy of treatment and potentially reducing the likelihood of cancer recurrence.
Used in Pharmaceutical Research:
Temozolomide serves as a subject of interest in pharmaceutical research, where scientists study its mechanisms of action, potential synergistic effects with other drugs, and ways to improve its delivery and bioavailability. This research can lead to the development of novel drug delivery systems and more effective treatment strategies for cancer patients.

Upstream product

• 1507-14-8 1-(2-hydroxyethyl)-3,7-dimethyl-3,7-dihydropurine-2,6-dione 
• 83-67-0 theobromine / 
• 107-06-2 1,2-dichloro-ethane 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 47043-84-5 1-(2-diethylamino-ethyl)-3,7-dimethyl-3,7-dihydro-purine-2,6-dione 

Relevant articles and documents

Compound for treating pneumonia and application thereof

The invention discloses a compound for treating pneumonia and application thereof, and relates to the technical field of medicines. The compound for treating pneumonia is a heterocyclic compound, a pharmaceutically acceptable salt of the heterocyclic compound and/or a pharmaceutically acceptable carrier of the heterocyclic compound. The compound for treating pneumonia has a significant improvementeffect on bacterial pneumonia, viral pneumonia, fungal pneumonia, immune pneumonia, mycoplasma pneumonia, chlamydia pneumonia and other pathogen pneumonia, and especially can significantly improve pathological damage of viral bacterial pneumonia. The heterocyclic compound involved in the compound for treating pneumonia is simple in synthesis method, is suitable for industrial production, and is more stable than natural analogues; the activity of the compound is remarkably superior to that of ribavirin, oseltamivir, cefazolin and penicillin G which are clinically first-line medicines, and theactivity of the compound is also remarkably superior to that of purine analogues A, B and C.

Synthesis, brain antihypoxic activity and cell neuroprotection of 1-substituted-3,7-dimethylxanthines

Five newly synthesised original compounds were investigated for cute toxicity, influence on hexobarbital sleeping time, effect on the locomotor activity, and brain antihypoxic activity. Two of the compounds were tested in a model of glutamate induced neurotoxicity in the brain cell culture using a cell viability test. Our studies indicate that compounds 2a-c and 4 prolonged the survival time of mice in the model of anoxic hypoxia. Only compound 3 expressed antihypoxic activity in the model of circulatory hypoxia, evaluated with a statistical significant increase of the survival time. Compound 4 (1-[3-(2,3,dihydro-3-oxobenzisosulfonazol-2-yl)-propyl]-3,7-dimethylxanthine) in concentration range 0.3-3 μM statistically significantly antagonised the gutamate induced neurotoxicity. Compound 4 is important for further investigations on in vivo models of brain dementia. (C) 2000 Editions scientifiques et medicales Elsevier SAS.